Epidemiology of chemotherapy-induced neutropenia at a tertiary university hospital in Oman

被引:7
作者
Abou Saleh, Maram [1 ]
Mafiana, Rose Ngozi [2 ]
Al Za'abi, Mohammed [1 ]
Vaishnav, Ragini [1 ]
Al Kindi, Salam [3 ]
Al-Zakwani, Ibrahim [1 ,4 ]
机构
[1] Sultan Qaboos Univ, Dept Pharmacol & Clin Pharm, Coll Med & Hlth Sci, Muscat, Oman
[2] Sultan Qaboos Univ Hosp, Dept Pharm, Muscat 123, Oman
[3] Sultan Qaboos Univ, Dept Hematol, Coll Med & Hlth Sci, Muscat, Oman
[4] Gulf Hlth Res, Muscat, Oman
关键词
Febrile neutropenia; Incidence; Length of hospital stay; Neutropenia; Oman; FEBRILE NEUTROPENIA; CANCER-PATIENTS; IMPACT;
D O I
10.1007/s11096-013-9859-8
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background Little is known about the incidence and burden of chemotherapy-induced neutropenia (CIN) in Oman or the Arabian Gulf. Objectives To determine the epidemiology of CIN at Sultan Qaboos University Hospital in Oman. Methods A retrospective observational study of all eligible CIN episodes in adult (> 18 years) patients with solid tumors and hematological malignancies at Sultan Qaboos University Hospital (SQUH) from January to December 2010. Analyses were performed using univariate statistics. Results A total of 1,357 episodes in 159 patients with a mean age of 50 +/- A 15 years (19-91) were evaluated. Fifty-four percent (n = 86) of the patients were female. A total of 46 % (73/159) of the patients developed CIN accounting for 15 % (210/1,357) of all episodes. Twelve percent (25/210) of these CIN episodes were associated with fever in 26 % (19/73) patients. There was significant association between CIN and chemotherapy regimen (P < 0.001), younger age (P < 0.001), low hemoglobin (Hb) levels (P < 0.001) and advanced cancer stage (P = 0.006). Conclusions This study suggests a high incidence of CIN in SQUH patients which resulted in chemotherapy delays, longer hospital stays, and inpatient mortality. CIN was significantly correlated with chemotherapy regimen, younger age, low Hb levels and cancer stage.
引用
收藏
页码:1036 / 1039
页数:4
相关论文
共 9 条
[1]   FEBRILE NEUTROPENIA IN CANCER-PATIENTS IN KUWAIT - MICROBIAL SPECTRUM AND OUTCOME [J].
ALBAHAR, S ;
PANDITA, R ;
DHABHAR, BN ;
ALBAHAR, E .
SUPPORTIVE CARE IN CANCER, 1994, 2 (06) :400-402
[3]   REDUCTION BY GRANULOCYTE COLONY-STIMULATING FACTOR OF FEVER AND NEUTROPENIA INDUCED BY CHEMOTHERAPY IN PATIENTS WITH SMALL-CELL LUNG-CANCER [J].
CRAWFORD, J ;
OZER, H ;
STOLLER, R ;
JOHNSON, D ;
LYMAN, G ;
TABBARA, I ;
KRIS, M ;
GROUS, J ;
PICOZZI, V ;
RAUSCH, G ;
SMITH, R ;
GRADISHAR, W ;
YAHANDA, A ;
VINCENT, M ;
STEWART, M ;
GLASPY, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (03) :164-170
[4]   2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer [J].
Hughes, WT ;
Armstrong, D ;
Bodey, GP ;
Bow, EJ ;
Brown, AE ;
Calandra, T ;
Feld, R ;
Pizzo, PA ;
Rolston, KVI ;
Shenep, JL ;
Young, LS .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (06) :730-751
[5]   Impact of effective prevention and management of febrile neutropenia [J].
Krell, D. ;
Jones, A. L. .
BRITISH JOURNAL OF CANCER, 2009, 101 :S23-S26
[6]   Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients [J].
Kuderer, NM ;
Dale, DC ;
Crawford, J ;
Cosler, LE ;
Lyman, GH .
CANCER, 2006, 106 (10) :2258-2266
[7]   FILGRASTIM IN PATIENTS WITH CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA - A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].
MAHER, DW ;
LIESCHKE, GJ ;
GREEN, M ;
BISHOP, J ;
STUARTHARRIS, R ;
WOLF, M ;
SHERIDAN, WP ;
KEFFORD, RF ;
CEBON, J ;
OLVER, I ;
MCKENDRICK, J ;
TONER, G ;
BRADSTOCK, K ;
LIESCHKE, M ;
CRUICKSHANK, S ;
TOMITA, DK ;
HOFFMAN, EW ;
FOX, RM ;
MORSTYN, G .
ANNALS OF INTERNAL MEDICINE, 1994, 121 (07) :492-501
[8]  
National Comprehensive Cancer Network (NCCN), 2013, GUID PREV TREATM CAN
[9]  
Wilson-Royalty M, 2002, J ONCOL PHARM PRACT, V7, P141